Trials / Completed
CompletedNCT04952467
Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101
An Open Label, Single-dose, Single-period Study to Assess the Pharmacokinetics, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-XEN1101 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Xenon Pharmaceuticals Inc. · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-XEN1101 in healthy adult male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 14C-XEN1101 | Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101 |
Timeline
- Start date
- 2021-07-14
- Primary completion
- 2021-10-04
- Completion
- 2021-10-04
- First posted
- 2021-07-07
- Last updated
- 2022-01-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04952467. Inclusion in this directory is not an endorsement.